Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring

Primary progressive multiple sclerosis (PPMS) shows a highly variable disease progression with poor prognosis and a characteristic accumulation of disabilities in patients. These hallmarks of PPMS make it difficult to diagnose and currently impossible to efficiently treat. This study aimed to identify plasma metabolite profiles that allow diagnosis of PPMS and its differentiation from the relapsing-remitting subtype (RRMS), primary neurodegenerative disease (Parkinson’s disease, PD), and healthy controls (HCs) and that significantly change during the disease course and could serve as surrogate markers of multiple sclerosis (MS)-associated neurodegeneration over time. We applied untargeted high-resolution metabolomics to plasma samples to identify PPMS-specific signatures, validated our findings in independent sex- and age-matched PPMS and HC cohorts and built discriminatory models by partial least square discriminant analysis (PLS-DA). This signature was compared to sex- and age-matched RRMS patients, to patients with PD and HC. Finally, we investigated these metabolites in a longitudinal cohort of PPMS patients over a 24-month period. PLS-DA yielded predictive models for classification along with a set of 20 PPMS-specific informative metabolite markers. These metabolites suggest disease-specific alterations in glycerophospholipid and linoleic acid pathways. Notably, the glycerophospholipid LysoPC(20:0) significantly decreased during the observation period. These findings show potential for diagnosis and disease course monitoring, and might serve as biomarkers to assess treatment efficacy in future clinical trials for neuroprotective MS therapies.

[1]  Robert S Plumb,et al.  Global metabolic profiling of animal and human tissues via UPLC-MS , 2012, Nature Protocols.

[2]  H. Piao,et al.  Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology , 2016, Neurochemical Research.

[3]  D. Paty,et al.  The natural history of primary progressive MS in British Columbia, Canada , 2005, Neurology.

[4]  D. Arnold,et al.  Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? , 2012, Acta Neuropathologica.

[5]  Matej Oresic,et al.  Normalization method for metabolomics data using optimal selection of multiple internal standards , 2007, BMC Bioinformatics.

[6]  S. Gold,et al.  Sex-related factors in multiple sclerosis susceptibility and progression , 2012, Nature Reviews Neurology.

[7]  Max Kuhn,et al.  caret: Classification and Regression Training , 2015 .

[8]  Kazuki Saito,et al.  Compensation for systematic cross-contribution improves normalization of mass spectrometry based metabolomics data. , 2009, Analytical chemistry.

[9]  Jun Feng Xiao,et al.  Metabolite identification and quantitation in LC-MS/MS-based metabolomics. , 2012, Trends in analytical chemistry : TRAC.

[10]  A. Zibetti,et al.  Significance of plasma lysolecithin in patients with multiple sclerosis: a longitudinal study , 1973, Journal of neurology, neurosurgery, and psychiatry.

[11]  David S. Wishart,et al.  MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..

[12]  Manuel A. Friese,et al.  Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis , 2014, Nature Reviews Neurology.

[13]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[14]  Gilles J. Guillemin,et al.  Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis , 2016, Front. Immunol..

[15]  Ignacio González,et al.  integrOmics: an R package to unravel relationships between two omics datasets , 2009, Bioinform..

[16]  O. Ciccarelli,et al.  Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS , 2012, Multiple sclerosis.

[17]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[18]  C. Lederer,et al.  Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review , 2014, PloS one.

[19]  R. Benedict,et al.  Lp-PLA2: Inflammatory Biomarker of Vascular Risk in Multiple Sclerosis , 2012, Journal of Clinical Immunology.

[20]  Lihua Jiang,et al.  Optimized Analytical Procedures for the Untargeted Metabolomic Profiling of Human Urine and Plasma by Combining Hydrophilic Interaction (HILIC) and Reverse-Phase Liquid Chromatography (RPLC)–Mass Spectrometry* , 2015, Molecular & Cellular Proteomics.

[21]  Thomas Lengauer,et al.  ROCR: visualizing classifier performance in R , 2005, Bioinform..

[22]  D. Berg,et al.  Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease , 2018, Front. Aging Neurosci..

[23]  R. Mutani,et al.  Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. , 1979, Journal of neurology, neurosurgery, and psychiatry.

[24]  D. Fuchs,et al.  Serum tryptophan, kynurenine, and neopterin in patients with Guillain-Barre-syndrome (GBS) and multiple sclerosis (MS). , 1996, Advances in experimental medicine and biology.

[25]  S. Gold.  Sex-Related Factors in Multiple Sclerosis , 2016 .

[26]  Jennifer A Kirwan,et al.  Direct infusion mass spectrometry metabolomics dataset: a benchmark for data processing and quality control , 2014, Scientific Data.

[27]  L. Barberini,et al.  1H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[28]  Pierre Grammond,et al.  Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis , 2018, Multiple sclerosis.

[29]  T. Pischon,et al.  Reliability of Serum Metabolite Concentrations over a 4-Month Period Using a Targeted Metabolomic Approach , 2011, PloS one.

[30]  P. Rieckmann,et al.  The natural history of primary progressive multiple sclerosis , 2009, Neurology.

[31]  E. Thévenot,et al.  Analysis of the Human Adult Urinary Metabolome Variations with Age, Body Mass Index, and Gender by Implementing a Comprehensive Workflow for Univariate and OPLS Statistical Analyses. , 2015, Journal of proteome research.

[32]  E. Ntzani,et al.  A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial , 2013, BMJ Open.

[33]  A. A. Farooqui.  Lipid Mediators in the Neural Cell Nucleus: Their Metabolism, Signaling, and Association with Neurological Disorders , 2009, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[34]  R. Abagyan,et al.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. , 2006, Analytical chemistry.

[35]  Jeffrey A. Cohen,et al.  Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function , 2017, The Lancet.

[36]  G. Siuzdak,et al.  Innovation: Metabolomics: the apogee of the omics trilogy , 2012, Nature Reviews Molecular Cell Biology.

[37]  R. Sandyk.  Tryptophan availability and the susceptibility to stress in multiple sclerosis: a hypothesis. , 1996, The International journal of neuroscience.

[38]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[39]  Bruce V. Taylor,et al.  Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression , 2017, Scientific Reports.

[40]  Rainer Breitling,et al.  IDEOM: an Excel interface for analysis of LC-MS-based metabolomics data , 2012, Bioinform..

[41]  Steffen Neumann,et al.  IPO: a tool for automated optimization of XCMS parameters , 2015, BMC Bioinformatics.

[42]  L. Horrocks,et al.  Phospholipase A₂-Generated Lipid Mediators in the Brain: The Good, the Bad, and the Ugly , 2006 .

[43]  I. Katz Sand.  Classification, diagnosis, and differential diagnosis of multiple sclerosis. , 2015, Current opinion in neurology.

[44]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[45]  R. Breitling,et al.  Toward global metabolomics analysis with hydrophilic interaction liquid chromatography-mass spectrometry: improved metabolite identification by retention time prediction. , 2011, Analytical chemistry.

[46]  M. Maletic-Savatic,et al.  Metabolomics of neurodegenerative diseases. , 2015, International review of neurobiology.

[47]  S. Böcker,et al.  Searching molecular structure databases with tandem mass spectra using CSI:FingerID , 2015, Proceedings of the National Academy of Sciences of the United States of America.

[48]  David S. Wishart,et al.  CFM-ID: a web server for annotation, spectrum prediction and metabolite identification from tandem mass spectra , 2014, Nucleic Acids Res..

[49]  M. Onofrj,et al.  Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. , 2011, Journal of proteomics.

[50]  M. Murakami,et al.  Phospholipase A2. , 2002, Journal of biochemistry.

[51]  Emma L. Schymanski,et al.  MetFrag relaunched: incorporating strategies beyond in silico fragmentation , 2016, Journal of Cheminformatics.

[52]  L. Barberini,et al.  1H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[53]  R. Breitling,et al.  PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass spectrometry data analysis. , 2011, Analytical chemistry.